Advantis

ADVT

Medical - Pharmaceuticals · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$9,785

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+38.2% over 3y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 708.2M (2015) → 978.5M (2018)

Advantis Corp. is a small specialty pharmaceutical company that develops and sells prescription drugs. It focuses on niche therapeutic areas, targeting patients and healthcare providers who need treatments that larger drug companies often overlook. The company operates in the specialty and generic drug manufacturing industry, where smaller firms compete by finding underserved medical needs.

Advantis makes money primarily through drug sales to pharmacies, hospitals, and distributors. Its very high gross margin of 92% suggests strong pricing power on its products, but a negative operating margin means it is currently spending more than it earns after overhead costs. The company appears to be in an early or growth stage, and its main challenge is reaching consistent profitability before it runs out of resources to fund operations.

--- *Note: Public financial data on Advantis Corp. (ADVT) is limited. This description is based on available sector context. Verify product details through official company filings before making any decisions.*

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

EPS data limited

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

100.0%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~1 months

$130,036 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Advantis has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial